Clariane SE (FRA:KO2) Cash Flow from Financing: €-623 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:KO2 Clariane SE FRA:KO2
56 GF Score
Price €4.07
GF Value €2.41
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Clariane SE Cash Flow from Financing?

Clariane SE FRA:KO2 +1.65% 56 Cash Flow from Financing is €-623 Mil as of Jun. 2026. GuruFocus rates FRA:KO2 with a GF Score™ of 56/100 and a GF Value™ of €2.41 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Jun. 2026, Clariane SE received €0 Mil more from issuing new shares than it paid to buy back shares. It received €607 Mil from issuing more debt. It paid €0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent €53 Mil paying cash dividends to shareholders. It spent €75 Mil on other financial activities. In all, Clariane SE earned €480 Mil on financial activities for the six months ended in Jun. 2026.


Clariane SE  (FRA:KO2) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Clariane SE's issuance of stock for the six months ended in Jun. 2026 was €0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Clariane SE's repurchase of stock for the six months ended in Jun. 2026 was €-0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Clariane SE's net issuance of debt for the six months ended in Jun. 2026 was €607 Mil. Clariane SE received €607 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Clariane SE's net issuance of preferred for the six months ended in Jun. 2026 was €0 Mil. Clariane SE paid €0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Clariane SE's cash flow for dividends for the six months ended in Jun. 2026 was €-53 Mil. Clariane SE spent €53 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Clariane SE's other financing for the six months ended in Jun. 2026 was €-75 Mil. Clariane SE spent €75 Mil on other financial activities.


Clariane SE Cash Flow from Financing Related Terms


Clariane SE Cash Flow from Financing Historical Data

* Premium members only.

The historical data trend for Clariane SE's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clariane SE Cash Flow from Financing Chart

Clariane SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.38 -550.13 -193.61 -1,106.96 -946.63

Clariane SE Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -622.17 -484.79 -60.19 -886.44 263.04
FRA:KO2
56GF Score
Clariane SE FRA:KO2
Cash Flow from Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clariane SE Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Clariane SE's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:

Clariane SE's Cash from Financing for the quarter that ended in Jun. 2026 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-623 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Financing of €-623 Mil mean?
Clariane SE (FRA:KO2) has a Cash Flow from Financing of €-623 Mil as of Jun. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Clariane SE and its competitors.
Is Clariane SE's Cash Flow from Financing too high?
Clariane SE's current Cash Flow from Financing is €-623 Mil. Overall, Clariane SE has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's Cash Flow from Financing compare to HCA and THC?
Clariane SE's Cash Flow from Financing of €-623 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Healthcare Providers & Services company?
A good Cash Flow from Financing depends on the Healthcare Providers & Services industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Clariane SE and its competitors. Clariane SE's current Cash Flow from Financing is €-623 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (FRA:KO2) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.41, compared to a current price of €4.07 — trading 69% above its estimated fair value. The current Cash Flow from Financing is €-623 Mil. Clariane SE's overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Clariane SE (FRA:KO2), the current Cash Flow from Financing is €-623 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clariane SE (FRA:KO2) Overvalued in 2026?

Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued. The current stock price of €4.07 is trading 69% above its estimated GF Value™ of €2.41. GuruFocus considers Clariane SE to be Significantly Overvalued.

Key valuation signals for FRA:KO2:

  • Cash Flow from Financing: €-623 Mil
  • GF Value™: €2.41 vs. price of €4.07 (69% above fair value)
  • GF Score™: 56/100 with 8 warning signs

No single metric tells the full story. See the FRA:KO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Clariane SE Business Description

Address 21-25, Rue Balzac, Paris, FRA, 75008
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
56GF Score

Get the complete analysis for FRA:KO2

Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.07
Price
€2.41
GF Value